NEW YORK (GenomeWeb News) – A class action lawsuit has been filed against Pacific Biosciences alleging the next-generation sequencing technology firm failed to disclose materially important information, which resulted in the artificial inflation of its stock price.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.